Cat. No.: HY-114360

Taurohyodeoxycholic acid

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula.

For research use only. We do not sell to patients.

Purity: 99.73%
CAS No.: 2958-04-5
Formula: C₂₆H₄₅NO₆S
Molecular Weight:499.70

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Taurohyodeoxycholic acid Chemical Structure

CAS No.: 2958-04-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Endogenous Metabolite Isoforms :

All COX Isoforms :

All Interleukin Related Isoforms :

All Glutathione Peroxidase Isoforms :

GPX1
GPX4

All TNF Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	24.2 μM Compound: 10a, tauro	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]

In Vitro

Taurohyodeoxycholic acid (25-100 μM, 12 h) dose-dependently decreases triglyceride levels in Palmitic acid (HY-N08307)/Oleic acid (HY-N1446)-treated AML-12 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Taurohyodeoxycholic acid (200 mg/kg, p.o., daily, 17 days) ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice by reducing lipid accumulation^[1].
Taurohyodeoxycholic acid (20-100 mg/kg, p.o. or i.g., daily, 7 days) alleviates trinitrobenzene sulfonic acid (TNBS) -induced colitis in mice^[2].
Taurohyodeoxycholic acid (4 mg/kg/min (8 μmol/min/kg), i.v., 1 h) prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

High-fat diet was fed to 4-week-old male C57BL/6 mice to induce nonalcoholic fatty liver disease^[1].
Dosage:

200 mg/kg
Administration:

p.o. daily for 17 days
Result:

Reduced body weight, liver index, and epididymal white adipose tissue index in high-fat diet-fed mice.
Decreased serum triglyceride, total cholesterol, and hepatic triglyceride levels.
Improved hepatic steatosis and glucose homeostasis (enhanced glucose tolerance and insulin sensitivity).
Upregulated hepatic CYP7B1 protein expression and downregulated hepatic CYP7A1 and CD36 protein expressions.
Dose-dependently decreased triglyceride levels in palmitic acid/oleic acid-treated AML-12 cells.

Animal Model:

Trinitrobenzene sulfonic acid (100 μL of 2.0 mg TNBS in 50% EtOH) was intrarectally administered to 7-8-week-old male SPF Kunming mice to induce ulcerative colitis^[2].
Dosage:

20, 40, 80 mg/kg
Administration:

p.o. daily for 7 days
Result:

Alleviated TNBS-induced colitis by improving body weight, colon length, spleen weight, histological characteristics, and reducing MPO activity in mice.
Reduced Th1-/Th17-related cytokines (IFN-γ, IL-12, p70, IL-6, IL-17A, IL-21, IL-22, TNF-α) and transcription factors (T-bet, STAT4, RORγt, STAT3) in the colon.
Increased Th2-/Treg-related cytokines (IL-4, IL-10, TGF-β1) and transcription factors (GATA3, STAT6, Foxp3, Smad3) in the colon.
Inhibited IFN-γ, IL-17A, T-bet, RORγt expressions and improved IL-4, IL-10, GATA3, Foxp3 expressions in the spleen.
Restored the proportion of Th1, Th2, Th17, Treg cells and balanced Th1/Th2 and Th17/Treg immune response in colitis mice.

Animal Model:

Taurochenodeoxycholic acid was intravenously infused into bile fistula Sprague-Dawley rats (200-250 g)^[3].
Dosage:

4 mg/kg/min (8 μmol/min/kg)
Administration:

i.v. for 1 h
Result:

Increased bile flow, with maximum flow rate twice that of the control group after 60 minutes.
Enhanced biliary secretion of total bile acids, reaching a maximum rate of 17.5 μmol/min/kg at 60 minutes; Increased phospholipid secretion, with a peak of 0.65 μmol/min/kg.
Restored biliary calcium secretion; reduced biliary leakage of alkaline phosphatase to levels similar to the control group and decreased lactate dehydrogenase leakage.
Increased the maximum biliary secretion rate of taurochenodeoxycholic acid to 7.6 μmol/min/kg, with its own maximum secretion rate reaching 7.9 μmol/min/kg.

Animal Model:

Trinitrobenzene sulfonic acid (TNBS, 0.5 mg in 0.1 ml of 50% ethanol) was intrarectally administered into the colon of 22-25 g male Balb/c mice via a 3.5F catheter inserted 4 cm proximal to the anus to induce ulcerative colitis model^[4].
Dosage:

25, 50, 100 mg/kg
Administration:

i.g., daily for 7 days
Result:

Alleviated TNBS-induced colitis by improving body weight, reducing macroscopic colonic damage and histopathological changes, and decreasing colonic MPO activity in mice.
Reduced serum levels of pro-inflammatory cytokines (TNF-α, IL-6) and decreased the expression of COX-2 in the colon.

Chemical Information

CAS No. 2958-04-5
Appearance Solid
Molecular Weight 499.70
Formula C₂₆H₄₅NO₆S
Color White to off-white
SMILES

C[C@@]12[C@]3([H])[C@](C[C@@H]([C@]1([H])C[C@@H](CC2)O)O)([H])[C@@]4([H])[C@](CC3)([C@@](CC4)([H])[C@H](C)CCC(NCCS(=O)(O)=O)=O)C
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Cell Host Microbe

Veillonella intestinal colonization promotes C. difficile infection in Crohn's disease. [Abstract]

2025 Aug 19:S1931-3128(25)00291-4. PMID: 40848719
Phytomedicine

Geniposide alleviated bile acid-associated NLRP3 inflammasome activation by regulating SIRT1/FXR signaling in bile duct ligation-induced liver fibrosis. [Abstract]

2023 Sep:118:154971. PMID: 37494875

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (200.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0012 mL

10.0060 mL

20.0120 mL

5 mM

0.4002 mL

2.0012 mL

4.0024 mL

10 mM

0.2001 mL

1.0006 mL

2.0012 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Roda A, et, al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27(2):520-5. [Content Brief]

[2]. Carubbi F, et, al. Comparative cytotoxic and cytoprotective effects of taurohyodeoxycholic acid (THDCA) and tauroursodeoxycholic acid (TUDCA) in HepG2 cell line. Biochim Biophys Acta. 2002 Jan 30;1580(1):31-9. [Content Brief]

[3]. Zheng N, et al. Astragalus polysaccharide attenuates nonalcoholic fatty liver disease through THDCA in high-fat diet-fed mice. J Ethnopharmacol. 2024 Feb 10;320:117401. [Content Brief]

[4]. Lv L, et al. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Life Sci. 2023 Apr 1;318:121501. [Content Brief]

[5]. Roda A, et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27(2):520-5. [Content Brief]

[6]. He J, et al. Protective effect of taurohyodeoxycholic acid from Pulvis Fellis Suis on trinitrobenzene sulfonic acid induced ulcerative colitis in mice. Eur J Pharmacol. 2011 Nov 16;670(1):229-35. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0012 mL	10.0060 mL	20.0120 mL	50.0300 mL
	5 mM	0.4002 mL	2.0012 mL	4.0024 mL	10.0060 mL
	10 mM	0.2001 mL	1.0006 mL	2.0012 mL	5.0030 mL
	15 mM	0.1334 mL	0.6671 mL	1.3341 mL	3.3353 mL
	20 mM	0.1001 mL	0.5003 mL	1.0006 mL	2.5015 mL
	25 mM	0.0800 mL	0.4002 mL	0.8005 mL	2.0012 mL
	30 mM	0.0667 mL	0.3335 mL	0.6671 mL	1.6677 mL
	40 mM	0.0500 mL	0.2502 mL	0.5003 mL	1.2508 mL
	50 mM	0.0400 mL	0.2001 mL	0.4002 mL	1.0006 mL
	60 mM	0.0334 mL	0.1668 mL	0.3335 mL	0.8338 mL
	80 mM	0.0250 mL	0.1251 mL	0.2502 mL	0.6254 mL
	100 mM	0.0200 mL	0.1001 mL	0.2001 mL	0.5003 mL

Keywords

Taurohyodeoxycholic acid

2 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Taurohyodeoxycholic acid

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Orally Active Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Bile Acids Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Taurohyodeoxycholic acid

All Endogenous Metabolite Isoforms

All COX Isoforms

All Interleukin Related Isoforms

All Glutathione Peroxidase Isoforms

All TNF Receptor Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Taurohyodeoxycholic acid Related Classifications

HY-114360 Related Classifications